{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:14:18Z","timestamp":1748405658299,"version":"3.41.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[1999,3]]},"DOI":"10.1023\/a:1026567226208","type":"journal-article","created":{"date-parts":[[2003,11,6]],"date-time":"2003-11-06T17:11:16Z","timestamp":1068138676000},"page":"91-96","source":"Crossref","is-referenced-by-count":1,"title":["The effect of latanoprost on aqueous humor PGF2\u03b1 levels in glaucoma patients"],"prefix":"10.1007","volume":"23","author":[{"given":"Dilek","family":"G\u00fcven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Karakurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdal","family":"Saban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikmet","family":"Hasiripi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"276775_CR1","first-page":"161","volume":"12","author":"ML Sears","year":"1973","unstructured":"Sears ML, Neufeld AH, Jampol LM. Editorials on recent advances: Prostaglandins. Investigative Ophthalmol 1973; 12: 161\u2013164.","journal-title":"Investigative Ophthalmol"},{"key":"276775_CR2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0014-4835(77)80043-2","volume":"Suppl","author":"KE. Eakins","year":"1977","unstructured":"Eakins KE. Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp. Eye Res. 1977; Suppl: 483\u2013498.","journal-title":"Exp. Eye Res"},{"key":"276775_CR3","doi-asserted-by":"crossref","unstructured":"Masferrer JL, Kulkarni PS. Cyclooxygenase-2 inhibitors: A new approach to the therapy of ocular inflammation. Surv Ophthalmol 1997; Suppl 2: S35- S40.","DOI":"10.1016\/S0039-6257(97)80005-7"},{"key":"276775_CR4","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0039-6257(97)80004-5","volume":"Suppl2","author":"N Bazan","year":"1997","unstructured":"Bazan N, Allan G. Signal transduction and gene expression in the eye: A contemporary view of the pro-inflammatory, anti-inflammatory and modulatory roles of prostaglandins and other bioactive lipids. Surv Ophthalmol 1997; Suppl 2: S23\u2013S34.","journal-title":"Surv Ophthalmol"},{"key":"276775_CR5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1001\/archopht.1997.01100160081013","volume":"115","author":"PL. Kaufman","year":"1997","unstructured":"Kaufman PL. Prostaglandins and cholinomimetics. Arch Ophthalmol 1997; 115: 911\u2013913.","journal-title":"Arch Ophthalmol"},{"key":"276775_CR6","doi-asserted-by":"crossref","unstructured":"Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol 1997; Suppl 2: S69- S75.","DOI":"10.1016\/S0039-6257(97)80010-0"},{"key":"276775_CR7","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0039-6257(97)80008-2","volume":"Suppl2","author":"JD Lindsey","year":"1997","unstructured":"Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow. Surv Ophthalmol 1997; Suppl 2: S53\u2013S59.","journal-title":"Surv Ophthalmol"},{"key":"276775_CR8","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0039-6257(97)80009-4","volume":"Suppl2","author":"CB Camras","year":"1997","unstructured":"Camras CB, Alm A. Initial clinical studies with prostaglandins and their analogues. Surv Ophthalmol 1997; Suppl 2: S61\u2013S68.","journal-title":"Surv Ophthalmol"},{"key":"276775_CR9","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0039-6257(97)80002-1","volume":"Suppl2","author":"LZ. Bito","year":"1997","unstructured":"Bito LZ. Prostaglandins: A new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol 1997; Suppl 2: S1\u2013S14.","journal-title":"Surv Ophthalmol"},{"key":"276775_CR10","first-page":"S93","volume":"Suppl2","author":"PFJ Hyong","year":"1997","unstructured":"Hyong PFJ, Rulo A, Greve E, Watson P, Aim A. The additive intraocular pressure-lowering effect of Latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol 1997; Suppl 2: S93\u2013S98.","journal-title":"Surv Ophthalmol"},{"key":"276775_CR11","first-page":"877","volume":"Suppl2","author":"M Diestelhorst","year":"1997","unstructured":"Diestelhorst M, Krieglstein GK, Lusky M, Nagasubramanian S. Clinical dose-regimen studies with Latanoprost, a new ocular hypotensive PGF2\u03b1 analogue. Surv Ophthalmol 1997; Suppl 2: 877\u2013881.","journal-title":"Surv Ophthalmol"},{"key":"276775_CR12","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/S0039-6257(97)80016-1","volume":"Suppl2","author":"A Alm","year":"1997","unstructured":"Alm A, Camras CB, Watson PG. Phase III Latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol 1997; Suppl 2: S105\u2013S110.","journal-title":"Surv Ophthalmol"},{"key":"276775_CR13","doi-asserted-by":"crossref","unstructured":"Mishima HK, Kiuchi Y, Takamatsu M, Racz P, Bito LZ. Circadian intraocular pressure management with Latanoprost: Diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol 1997; Suppl 2: S139- S144.","DOI":"10.1016\/S0039-6257(97)80021-5"},{"key":"276775_CR14","first-page":"312","volume":"24","author":"LZ Bito","year":"1983","unstructured":"Bito LZ, Draga A, Blanco J, Camras CB. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes. Invest Ophthalmol Vis Sci 1983; 24: 312\u2013319.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"276775_CR15","first-page":"1087","volume":"25","author":"P Lee","year":"1984","unstructured":"Lee P, Podos SM, Severin C. Effect of prostaglandin F2\u03b1 on aqueous humor dynamics of rabbit, cat, and monkey. Invest Ophthalmol Vis Sci 1984; 25: 1087\u20131093.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"276775_CR16","doi-asserted-by":"crossref","first-page":"2l4","DOI":"10.1136\/bjo.76.4.214","volume":"76","author":"J Villumsen","year":"1992","unstructured":"Villumsen J, Alm A. PhXA34-a prostaglandin F2\u03b1\n analogue. Effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992; 76: 2l4\u2013217.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"276775_CR17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0090-6980(89)90140-8","volume":"38","author":"HHD Meyer","year":"1989","unstructured":"Meyer HHD, Ersele K, Osaso J. A biotin-streptavidin amplified enzyme immunoassay for 13,14-dihydro-15-keto-PGF2\u03b1\n. Prostaglandins 1989; 38(3): 375\u2013383.","journal-title":"Prostaglandins"},{"key":"276775_CR18","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0039-6257(97)80012-4","volume":"Suppl2","author":"PFJ Hoyng","year":"1997","unstructured":"Hoyng PFJ, Rulo AH, Greve EL, Astin M, Gj\u00f6tterberg M. Fluorescein angiographic evaluation of the effect of Latanoprost treatment on blood-retinal barrier integrity: A review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol 1997; Suppl 2: S83\u2013S88.","journal-title":"Surv Ophthalmol"},{"key":"276775_CR19","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0039-6257(97)80003-3","volume":"Suppl2","author":"DF Woodward","year":"1997","unstructured":"Woodward DF, Regan JW, Lake S, Ocklind A. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol 1997; Suppl 2: S15\u2013S21.","journal-title":"Surv Ophthalmol"},{"key":"276775_CR20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0886-3350(13)80390-2","volume":"18","author":"K Miyake","year":"1992","unstructured":"Miyake K, Shirasawa E, Hikita M. Active transport system of prostaglandins: Clinical implications and considerations. J Cataract Refract Surg 1992; 18: 100\u2013105.","journal-title":"J Cataract Refract Surg"},{"key":"276775_CR21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0014-4835(87)80045-3","volume":"44","author":"LZ Bito","year":"1987","unstructured":"Bito LZ, Baroody RA, Miranda OC. Eicosanoids as a new class of ocular hypotensive agents. 1. The apparent therapeutic advantages of derived prostaglandins of the A and B type as compared with primary prostaglandins of the E, F and D type. Exp Eye Res 1987; 44: 825\u2013837.","journal-title":"Exp Eye Res"},{"key":"276775_CR22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00055735-199604000-00003","volume":"7","author":"J Stjernchantz","year":"1996","unstructured":"Stjernchantz J, Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Current Opinion in Ophthalmology 1996; 7: 11\u201317.","journal-title":"Current Opinion in Ophthalmology"},{"key":"276775_CR23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3109\/02713688809001881","volume":"7","author":"K Green","year":"1988","unstructured":"Green K, Cheeks L, Luxenber MN. Topical indomethacin and prostaglandins in normal and aphakic eyes. Current Eye Research 1988; 7: 1105\u20131111.","journal-title":"Current Eye Research"},{"key":"276775_CR24","first-page":"1217","volume":"27","author":"PFJ Hoyng","year":"1986","unstructured":"Hoyng PFJ, Verbey N, Th\u00f6rig L, van Haeringen NJ. Topical prostaglandins inhibit trauma-induced inflammation in the rabbit. Invest Ophthalmol Vis Sci 1986; 27: 1217\u20131225.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"276775_CR25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/archopht.1983.01040010277019","volume":"101","author":"KL Wong","year":"1983","unstructured":"Wong KL, Howes EL. Intraocular injection of prostaglandins: Modification of response to circulating bacterial endotoxin. Arch Ophthalmol 1983; 101: 275\u2013279.","journal-title":"Arch Ophthalmol"},{"key":"276775_CR26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000267119","volume":"23","author":"JL van Delft","year":"1991","unstructured":"van Delft JL, van Haeringen NJ, Bodelier VM, Barthen ER, Oosterhuis JA. Prostaglandin E2 in the vitreous body of the normal rabbit eye and after ocular trauma. Ophthalmic Res 1991; 23: 240\u2013245.","journal-title":"Ophthalmic Res"},{"key":"276775_CR27","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0161-6420(97)30110-9","volume":"104","author":"AH Rulo","year":"1997","unstructured":"Rulo AH, Greve EL, Hoyng PFJ. Additive ocular hypotensive effect of Latanoprost and acetazolamide: A short-term study in patients with elevated intraocular pressure. Ophthalmology 1997; 104: 1503\u20131507.","journal-title":"Ophthalmology"},{"key":"276775_CR28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3891\/acta.chem.scand.46-0108","volume":"46","author":"S Basu","year":"1992","unstructured":"Basu S, Sj\u00f6quist B, Resul B, Stjernschantz J. Presence of a 15-ketoprostaglandin 113-reductase in porcine cornea. Acta Chemica Scandinavica 1992; 46: 108\u2013110.","journal-title":"Acta Chemica Scandinavica"},{"key":"276775_CR29","first-page":"44","volume":"4","author":"A. Alm","year":"1993","unstructured":"Alm A. The potential of prostaglandin derivates in glaucoma therapy. Current Opinion in Ophthalmology 1993; 4: 44\u201350.","journal-title":"Current Opinion in Ophthalmology"},{"key":"276775_CR30","first-page":"63","volume-title":"Advances in Prostaglandin, Thromboxane, and Leukotriene Research","author":"J. Stjernschantz","year":"1995","unstructured":"Stjernschantz J. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Vol. 23, B. Samuelsson et al. (ed). Raven Press Ltd., New York, 1995; 63\u201368."},{"key":"276775_CR31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0161-6420(98)92977-3","volume":"105","author":"RE Warwar","year":"1998","unstructured":"Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with Latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998; 105: 263\u2013268.","journal-title":"Ophthalmology"},{"key":"276775_CR32","first-page":"679","volume":"116","author":"A Avakian","year":"1998","unstructured":"Avakian A, Renier SA, Butler PJ. Adverse effects of Latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol 1998; 116: 679\u2013680.","journal-title":"Arch Ophthalmol"},{"key":"276775_CR33","first-page":"680","volume":"116","author":"JS Heier","year":"1998","unstructured":"Heier JS, Wayne F, Steinert RF, Frederick AR. Cystoid macular edema associated with Latanoprost use. Arch Ophthalmol1998; 116: 680\u2013682.","journal-title":"Arch Ophthalmol"},{"key":"276775_CR34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0002-9394(14)70907-9","volume":"124","author":"J Rowe","year":"1997","unstructured":"Rowe J, Hattenhauer MG, Herman DC. Adverse side effects associated with Latanoprost. Am J Ophthalmol 1997; 124: 683\u2013685.","journal-title":"Am J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1026567226208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1026567226208\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1026567226208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:19:23Z","timestamp":1748351963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1026567226208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["276775"],"URL":"https:\/\/doi.org\/10.1023\/a:1026567226208","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"type":"print","value":"0165-5701"},{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[1999,3]]}}}